Weight-loss medicines are rising in popularity. According to some estimates, this market will be worth $44 billion in risk-adjusted sales by 2030, while it was only valued at $2.5 billion last year. Naturally, several biotech giants will dominate this industry, the two most important (by some margin) being Novo Nordisk and Eli Lilly.

While both stocks are well worth investing in, one smaller company in this space might have an even more substantial upside potential: Viking Therapeutics (NASDAQ: VKTX). While not a household name, this stock could deliver market-beating returns through the end of the decade. Let's find out why.

Viking Therapeutics is a clinical-stage biotech, with only four programs in its pipeline. The biotech's leading therapy is called VK2809, a potential treatment for non-alcoholic steatohepatitis (NASH). There aren't any approved treatments for it yet although that should change within the next year or so. The NASH market is also projected to skyrocket in the coming years.

Continue reading

Source Fool.com